| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2024―Apr―19 |
Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks |
Jiajun Xu, Raghad Abdulsalam Khaleel, Haider Kamil Zaidan, Ahmed Faisal Mutee, Khaled Fahmi Fawy, Anita Gehlot, et al. (+7) Alaa Hashim Abbas, José Luis Arias Gonzáles, Ali H Amin, Maribel Carmen Ruiz-Balvin, Shima Imannezhad, Abolfazl Bahrami, Reza Akhavan-Sigari |
| 2 |
[GO] |
2023―Jul―24 |
COVID-19 of differing severity: from bulk to single-cell expression data analysis |
Linlin Tian, Min He, Huafeng Fan, Hongying Zhang, Xiaoxiao Dong, Mengkai Qiao, et al. (+4) Chenyu Tang, Yan Yu, Tong Chen, Nan Zhou |
| 3 |
[GO] |
2022―Jul―19 |
Application of emetine in SARS-CoV-2 treatment: regulation of p38 MAPK signaling pathway for preventing emetine-induced cardiac complications |
Mehdi Valipour, Hamid Irannejad, Saeed Emami |
| 4 |
[GO] |
2021―Sep―29 |
Therapeutic potential of chelerythrine as a multi-purpose adjuvant for the treatment of COVID-19 |
Mehdi Valipour, Afshin Zarghi, Mohammad Ali Ebrahimzadeh, Hamid Irannejad |
| 5 |
[GO] |
2020―Dez―31 |
MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents? |
Farshad Abedi, Ramin Rezaee, A. Wallace Hayes, Somayyeh Nasiripour, Gholamreza Karimi |
| 6 |
[GO] |
2020―Dez―11 |
Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine -possible therapeutic implication |
Mehrdad Ghashghaeinia, Peter Dreischer, Thomas Wieder, Martin Köberle |
| 7 |
[GO] |
2020―Dez―11 |
Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2. |
Neil D. Theise, Anthony R. Arment, Dimple Chakravarty, John M. H. Gregg, Ira M. Jacobson, Kie Hoon Jung, et al. (+5) Sujit S. Nair, Ashutosh K. Tewari, Archie W. Thurston, John Van Drie, Jonna B. Westover |
|
